298 related articles for article (PubMed ID: 23953834)
1. [Off-label use of recombinant factor VII (rFVIIa) in teaching hospitals in Paris in 2010].
Bardon J; Fink J; de Montblanc J; Bergmann JF; Sarrut B; Benhamou D
Ann Fr Anesth Reanim; 2013 Oct; 32(10):659-64. PubMed ID: 23953834
[TBL] [Abstract][Full Text] [Related]
2. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).
Hacquard M; Durand M; Lecompte T; Boini S; Briançon S; Carteaux JP
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1320-7. PubMed ID: 21550261
[TBL] [Abstract][Full Text] [Related]
3. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
Guzzetta NA; Russell IA; Williams GD
Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA;
Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520
[TBL] [Abstract][Full Text] [Related]
5. Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland.
Donovan PJ; Iedema J; McLeod DS; Kubler P; Pillans P
ANZ J Surg; 2013 Mar; 83(3):149-54. PubMed ID: 23137066
[TBL] [Abstract][Full Text] [Related]
6. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).
Karkouti K; Arellano R; Aye T; Dupuis JY; Kent B; Lee TW; Lin Y; Ralley F; MacAdams C; Mazer CD; Muirhead B; Rheault MR; Rochon A; Syed S; Waters T; Wong B
Can J Anaesth; 2014 Aug; 61(8):727-35. PubMed ID: 24890696
[TBL] [Abstract][Full Text] [Related]
7. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
[TBL] [Abstract][Full Text] [Related]
8. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
[TBL] [Abstract][Full Text] [Related]
9. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
10. Variation in the use of recombinant activated factor VII in critical bleeding.
Willis CD; Cameron PA; Phillips L
Intern Med J; 2010 Jul; 40(7):486-93. PubMed ID: 19712199
[TBL] [Abstract][Full Text] [Related]
11. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.
Logan AC; Yank V; Stafford RS
Ann Intern Med; 2011 Apr; 154(8):516-22. PubMed ID: 21502649
[TBL] [Abstract][Full Text] [Related]
12. Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy.
Zaaroor M; Soustiel JF; Brenner B; Bar-Lavie Y; Martinowitz U; Levi L
Acta Neurochir (Wien); 2008 Jul; 150(7):663-8. PubMed ID: 18473114
[TBL] [Abstract][Full Text] [Related]
13. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
Pham HP; Hsu SX; Parker-Jones S; Samstein B; Diuguid D; Schwartz J
Vox Sang; 2014 Jan; 106(1):75-82. PubMed ID: 23815226
[TBL] [Abstract][Full Text] [Related]
14. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
15. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.
Yank V; Tuohy CV; Logan AC; Bravata DM; Staudenmayer K; Eisenhut R; Sundaram V; McMahon D; Olkin I; McDonald KM; Owens DK; Stafford RS
Ann Intern Med; 2011 Apr; 154(8):529-40. PubMed ID: 21502651
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
[TBL] [Abstract][Full Text] [Related]
17. Recombinant activated factor VII use in critically ill infants with active hemorrhage.
Jen H; Shew S
J Pediatr Surg; 2008 Dec; 43(12):2235-8. PubMed ID: 19040942
[TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VII (rFVIIa/NovoSeven®) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan.
Kobayashi T; Nakabayashi M; Yoshioka A; Maeda M; Ikenoue T
Int J Hematol; 2012 Jan; 95(1):57-63. PubMed ID: 22160834
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven
Marsh K; Green D; Raco V; Papadopoulos J; Ahuja T
Ther Adv Cardiovasc Dis; 2020; 14():1753944720924255. PubMed ID: 32449469
[TBL] [Abstract][Full Text] [Related]
20. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
